Actavis rejected $15 billion offer from Mylan - source

Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.

Mylan's cash and stock bid for its larger rival, which came in early last week, valued Actavis at $120 per share, the person said, asking not to be identified because the matter is not public.

 

The Mylan offer came shortly after Actavis halted discussions with Canadian drugmaker Valeant Pharmaceuticals International Inc about selling itself for more than $13 billion, the person said.

Canonsburg, Pennsylvania-based Mylan is no longer actively pursuing a deal after shares of Actavis rose significantly over the past week, to above its $120 per share offer, the person added.

Actavis shares ended Tuesday at $121.68 on the New York Stock Exchange, valuing the company at more than $15.5 billion. Mylan shares rose 3 percent to $30.10, making the company worth about $11.5 billion.

An Actavis spokesman and a Mylan spokeswoman declined to comment. News of Mylan's offer and its rejection by Actavis was first reported by Bloomberg.

Actavis said on Friday it is in preliminary talks to acquire specialty pharmaceutical company Warner Chilcott Plc.

Popular posts from this blog

'I was his Christian Grey fantasy.' Ex-girlfriend Paige Lorenze says Armie Hammer carved an A into her groin area as she warns 'narcissistic' actor could 'seriously injure another woman' with his BDSM obsession

Model Stella Tennant dies 'suddenly' aged 50 as her family pay tribute to 'wonderful woman and an inspiration to us all'

Teenage boy, 15, charged after allegedly having sex with two 12-year-old girls and recording the encounter on his phone - but he's still allowed to go to school with them while on bail